A New Iboga Microdosing Study Raises Important Questions for Brain Injury Recovery
A fascinating new case series has added to the growing conversation around psychedelics and brain injury recovery. The study explored the effects of an integrative iboga microdosing protocol in three individuals living with persistent symptoms following brain injury. The participants included two individuals with traumatic brain injury (TBI) and one individual with a chronic hypoxic brain injury.
The intervention consisted of a six-week microdosing protocol using Tabernanthe iboga root bark, administered on a four-days-on, three-days-off schedule, alongside weekly Accelerated Experiential Dynamic Psychotherapy (AEDP). AEDP is a somatically oriented therapeutic approach that draws heavily on emotional processing, attachment theory, trauma work and experiential techniques. Participants were followed beyond the active treatment period, with follow-up assessments occurring between approximately three and five months after completion of the protocol.
Across the three cases, participants reported improvements in a broad range of symptoms commonly associated with brain injury. These included reductions in headaches, migraines, fatigue, brain fog, dizziness, sleep disturbances and emotional dysregulation. Improvements were also reported in cognitive clarity, memory, concentration, emotional resilience and overall quality of life. Several participants described a return to meaningful activities that had previously become difficult or impossible, including work, study, exercise and social engagement.
In recent years, a growing body of research has begun exploring the potential role of psychedelics in brain injury recovery, with ibogaine attracting increasing attention. Most notably, recent research involving military veterans reported significant improvements in traumatic brain injury symptoms following ibogaine treatment, helping to shift the conversation from theoretical possibility towards genuine clinical interest.
While only involving three participants, the pattern of improvements reported across physical, cognitive and emotional domains appears broadly consistent with themes beginning to emerge elsewhere in the literature. Taken together, these findings raise an exciting possibility: that psychedelics may have a meaningful role to play in supporting recovery following brain injury.
What also caught my attention was how closely some of these findings mirrored themes identified in my own qualitative research exploring psychedelic use following brain injury. While my study examined a range of psychedelic substances rather than iboga specifically, participants similarly described reductions in emotional distress, periods of improved cognitive functioning, and perhaps most interestingly, a greater sense of acceptance, self-understanding and reconciliation with life after injury. Seeing these themes emerge independently within a separate study raises the possibility that psychedelics may not only influence symptom reduction but also support the process of identity reconstruction following brain injury, helping individuals develop a greater sense of acceptance, self-compassion and connection to who they are beyond the injury itself.
Beyond the Scientific Framework
One caveat raised by the authors is that we cannot know how much of the improvement was due to the iboga protocol itself, and how much was related to the accompanying psychotherapy. That's a fair scientific limitation. However, when I read the paper, I found myself questioning whether this caveat should carry quite as much weight as it is often given.
The improvements reported weren't limited to emotional wellbeing. Across the three cases, participants described reductions in headaches, fatigue, brain fog, dizziness, sleep disruption and other neurological symptoms. While the psychotherapy may well have contributed to improvements in mood, acceptance and emotional processing, AEDP is not currently an established treatment for post-concussive headaches, cognitive dysfunction or neurological recovery following brain injury. If someone wishes to argue that the therapy was responsible for the observed changes, then the burden becomes explaining how six weeks of psychotherapy alone produced improvements across such a broad range of physical and cognitive symptoms.
What also stands out is that these were not people who had simply developed symptoms a few weeks earlier. Two of the participants had been living with persistent symptoms for months and years despite previous medical care, medications, supplements and other interventions. One participant had been experiencing difficulties for approximately seven years following a hypoxic brain injury. When longstanding symptoms begin to improve during a defined intervention period, it becomes increasingly difficult to dismiss the observation as merely spontaneous recovery.
For me, the more interesting question is not whether these participants improved. They clearly did. The more interesting question is how much of that improvement can reasonably be attributed to the iboga protocol itself, how much came from the psychotherapy, and whether the true therapeutic effect lies in the interaction between the two. My suspicion is that the psychotherapy may help explain some of the emotional and identity-related changes, but it is harder to ignore the possibility that iboga played a meaningful role in the physical and cognitive improvements that were observed.
Of course, the authors are careful not to overstate their conclusions. Throughout the paper they repeatedly remind readers that this was a small case series, that causality cannot be established, and that improvements may have been influenced by factors other than iboga. This is entirely understandable. Academic researchers operate within a scientific framework that demands caution, particularly when discussing psychedelic substances. Their role is not to make bold claims, but to present observations and acknowledge every plausible alternative explanation.
However, when viewed outside of that framework, the findings become harder to dismiss. If we step back from the obligatory disclaimers and simply look at what happened, we see individuals with longstanding and often debilitating symptoms reporting improvements in headaches, fatigue, cognitive clarity, emotional regulation and overall quality of life. We see people returning to activities they had lost, rebuilding relationships, and in some cases describing themselves as feeling better than they had in years. Whether one ultimately attribute those changes to iboga, psychotherapy, or some combination of factors, the observations themselves remain compelling.
This is perhaps the tension that runs through much of psychedelic research. Psychedelics have always had a curious relationship with systems, categories and established ways of thinking. They are substances that routinely generate experiences of psychological flexibility, new perspectives and the questioning of previously held assumptions. Yet our primary method for understanding them is through scientific frameworks that necessarily seek to reduce complexity, isolate variables and fit phenomena into predefined models. There is a certain paradox in that. We are attempting to understand compounds that often challenge existing frameworks by examining them almost exclusively from within those same frameworks.
What’s Next?
What I would like to see next is a study that directly examines whether the symptomatic improvements reported during an iboga microdosing protocol are accompanied by measurable changes in the brain. Recent ibogaine research in veterans with traumatic brain injury has already begun moving in this direction, successfully identifying structural and functional brain changes alongside significant clinical improvements. A similar approach could be applied to microdosing.
For example, participants could complete a six-week or twelve-week iboga microdosing protocol, with assessments before and after treatment. MRI could be used to examine structural changes, white matter integrity or broader markers of brain recovery, while MEG or EEG could help explore changes in brain network activity, cortical rhythms or neural complexity.
What would be particularly fascinating is whether a longer microdosing protocol produces more pronounced changes. Would a twelve-week protocol show stronger effects than six weeks? If structural or functional brain changes are occurring, do they continue to accumulate over time, or is there a plateau beyond which additional dosing provides little added benefit?
The therapy question also needs careful thought. From a purely scientific perspective, researchers may want to isolate the effects of iboga by removing psychotherapy as a variable. But from a clinical and ethical perspective, I am not sure this is straightforward. Psychedelics can bring unconscious material to the surface. Asking someone to go through that process without adequate therapeutic support may not be appropriate, especially in a brain injury population where emotional regulation, fatigue and cognitive vulnerability are already major considerations.
So perhaps the goal should not simply be to separate the medicine from the therapy, but to understand the relationship between them. Does iboga open a window of neuroplasticity? Does therapy help direct that window towards emotional integration and identity reconstruction? And could neurorehabilitation itself become part of that process?
Link to Study
Tabaac, B. J., Carhart-Harris, R. L., & Yung, T. (2026). Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: A case series. Frontiers in Pharmacology, 17, 1840956. https://doi.org/10.3389/fphar.2026.1840956
Additional References
Reed, O. (2025) Exploring the potential of psychedelics in brain injury recovery: A thematic analysis of participant narratives. https://www.researchgate.net/publication/403758971_Exploring_the_potential_of_Psychedelics_in_Brain_Injury_Recovery_A_Thematic_Analysis_of_Participant_Narratives